To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus

NCT05075408 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

258

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease Associated Moderate to Severe Pruritus

Interventions

DRUG: Nemolizumab
DRUG: Nemolizumab
DRUG: Placebo

Sponsor

Galderma R&D